Meeting
2021 ASCO Annual Meeting
MATTERHORN: Efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer—A randomized, double-blind, placebo-controlled, phase 3 study.
Authors
Yelena Y. Janjigian
Memorial Sloan Kettering Cancer Center, New York, NY
Yelena Y. Janjigian , Eric Van Cutsem , Kei Muro , Zev A. Wainberg , Salah-Eddin Al-Batran , Woo Jin Hyung , Daniela Molena , Brent Evans , Dario Ruscica , Scott H. Robbins , Alejandra Negro , Josep Tabernero
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT04592913
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS4151)
DOI
10.1200/JCO.2021.39.15_suppl.TPS4151
Abstract #
TPS4151
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
KEYNOTE-585: Phase 3 study of chemotherapy (chemo) + pembrolizumab (pembro) vs chemo + placebo as neoadjuvant/adjuvant treatment for patients (pts) with gastric or gastroesophageal junction (G/GEJ) cancer.
First Author: Yung-Jue Bang
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Randomized phase II study comparing neoadjuvant FLOT versus DOS for patients with type 4 or large type 3 gastric cancer (JCOG2204).
First Author: Izuma Nakayama
First Author: Salah-Eddin Al-Batran
Poster
2021 ASCO Annual Meeting
MONEO: A phase II study of avelumab (Av) plus FLOT in the peri-operative treatment for patients (pts) with resectable gastric or gastroesophageal junction cancer (GC).
First Author: MARIA ALSINA